VGXI, Inc. Names James Smith as New Chief Accounting Officer

Share Article

Industry-recognized plasmid DNA contract manufacturer VGXI, Inc. expands its leadership team with the addition of James Smith as Chief Accounting Officer.

VGXI CAO - James Smith
We are thrilled to welcome [Jim] to VGXI's leadership team and are confident that his skills and experience will help drive our continued growth and success.

VGXI Inc., a leading contract development and manufacturing organization (CDMO) for plasmid DNA, is pleased to announce the appointment of Mr. James Smith as its new Chief Accounting Officer (CAO). Mr. Smith brings over 15 years of experience in accounting and leadership positions across a variety of industries and disciplines, including healthcare and manufacturing.

Prior to joining VGXI, Mr. Smith worked in various roles including public accounting, private industry, and independent consulting. He has developed a deep financial understanding and demonstrated a track record of delivering high-quality financial results.

"Jim is an accomplished accounting executive with a wealth of experience, including specialized expertise related to the biotech industry and VGXI’s business operations," said VGXI's President and CEO, Young Park. "We are thrilled to welcome him to VGXI's leadership team and are confident that his skills and experience will help drive our continued growth and success."

Mr. Smith holds a B.A in Business Administration-Accounting from West Virginia University and currently holds designations for Certified Public Accountant (CPA), Certified Global Management Accountant (CGMA), and Certified Forensic Accountant (CrFA). In his new role at VGXI, Mr. Smith will oversee all of the company's accounting and financial operations at both its legacy location in The Woodlands, TX, and the new VGXI headquarters and manufacturing facility at Deison Technology Park in Conroe, TX.

With over 20 years of experience VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and highly experienced development team. VGXI, Inc. is a GeneOne company.
To learn more, visit

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II).
For more information, visit

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christy Franco
Like >

Visit website